title: How many genomics targets can a portfolio afford?
abstract: The pharmaceutical industry can look back at a history of successful innovations. Although genomics technologies have provided drug discovery pipelines with a plethora of new potential drug targets, solid target validation is crucial to avoiding high attrition rates. Biomarkers for patient stratification and approaches for personalized medicine will further help to reduce the risk associated with new targets. To achieve an overall risk balance, portfolios have to be supplemented with precedented targets, me-too approaches and line extensions of existing drugs. However, capitalizing on genomics investments and working on unprecedented targets is essential for a continuous stream of innovative drugs.
authors.affiliation: Bayer HealthCare, Pharma Research & Development, Apratherweg, D-42096 Wuppertal, Germany. ulrichbetz@yahoo.de
authors.forename: Ulrich A K
authors.initials: UA
authors.lastname: Betz
mesh_terms: D004345:Drug Industry / Q000191:economics* / Q000639:trends*; D004526:Efficiency; D023281:Genomics / Q000191:economics* / Q000639:trends*